Roth Capital Issues Negative Forecast for biote Earnings

biote Corp. (NASDAQ:BTMD) – Equities researchers at Roth Capital lowered their Q4 2024 earnings per share (EPS) estimates for biote in a research report issued on Wednesday, November 13th. Roth Capital analyst G. Kelly now expects that the company will post earnings per share of $0.13 for the quarter, down from their prior forecast of $0.19. The consensus estimate for biote’s current full-year earnings is $0.53 per share. Roth Capital also issued estimates for biote’s Q1 2025 earnings at $0.13 EPS, Q2 2025 earnings at $0.16 EPS, Q3 2025 earnings at $0.18 EPS, Q4 2025 earnings at $0.20 EPS and FY2025 earnings at $0.67 EPS.

biote Trading Down 2.2 %

NASDAQ BTMD opened at $6.57 on Thursday. biote has a 12 month low of $3.65 and a 12 month high of $8.44. The stock has a 50 day moving average of $5.53 and a 200-day moving average of $6.28. The company has a market cap of $356.23 million, a PE ratio of 25.85 and a beta of 0.94.

Institutional Trading of biote

A number of large investors have recently added to or reduced their stakes in BTMD. WINTON GROUP Ltd boosted its position in biote by 7.0% during the second quarter. WINTON GROUP Ltd now owns 47,725 shares of the company’s stock worth $357,000 after purchasing an additional 3,124 shares during the period. Allspring Global Investments Holdings LLC bought a new position in biote in the 2nd quarter valued at about $42,000. MetLife Investment Management LLC lifted its position in biote by 129.1% during the third quarter. MetLife Investment Management LLC now owns 16,582 shares of the company’s stock worth $93,000 after acquiring an additional 9,343 shares during the last quarter. The Manufacturers Life Insurance Company bought a new stake in shares of biote during the second quarter worth approximately $84,000. Finally, Rhumbline Advisers grew its position in shares of biote by 104.2% in the second quarter. Rhumbline Advisers now owns 28,225 shares of the company’s stock valued at $211,000 after purchasing an additional 14,404 shares during the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.